{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:11:06Z","timestamp":1795043466467,"version":"4.10.2"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T00:00:00Z","timestamp":1682812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153155"],"award-info":[{"award-number":["PJT-153155"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, &amp; Immunity - Health"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.bbih.2023.100635","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T02:57:02Z","timestamp":1683255422000},"page":"100635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Interleukin-6 as a marker of Huntington's disease progression: Systematic review and meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"given":"Sarah","family":"Eide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Misztal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2454-4462","authenticated-orcid":false,"given":"Zhong-Ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbih.2023.100635_bib1","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1080\/00207450701392068","article-title":"Cytokines in Alzheimer's disease and vascular dementia","volume":"118","author":"Angelopoulos","year":"2008","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.bbih.2023.100635_bib2","series-title":"Statistical Methods in Medical Research","author":"Armitage","year":"2008"},{"key":"10.1016\/j.bbih.2023.100635_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1582-4934.2010.01011.x","article-title":"Early defect of transforming growth factor \u03b21 formation in Huntington's disease","volume":"15","author":"Battaglia","year":"2011","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.bbih.2023.100635_bib4","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bj\u00f6rkqvist","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbih.2023.100635_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3233\/JHD-160213","article-title":"Plasma cytokine levels in relation to neuropsychiatric symptoms and cognitive dysfunction in Huntington's disease","volume":"5","author":"Bouwens","year":"2016","journal-title":"J. Huntingtons. Dis"},{"key":"10.1016\/j.bbih.2023.100635_bib6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mds.26950","article-title":"Disease stage and plasma levels of cytokines in Huntington's disease: a 2-year follow-up study","volume":"32","author":"Bouwens","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbih.2023.100635_bib7","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.27653","article-title":"Huntington's disease in the United States: variation by demographic and socioeconomic factors","volume":"34","author":"Bruzelius","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbih.2023.100635_bib8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis","volume":"16","author":"Byrne","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington's disease patients and mouse model","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2023.100635_bib10","first-page":"259","article-title":"Can human fetal cortical brain tissue transplant (up to 20 weeks) sustain its metabolic and oxygen requirements in a heterotopic site outside the brain? A study of 12 volunteers with Parkinson's disease","volume":"29","author":"Chhetri","year":"2002","journal-title":"Clin. Exp. Obstet. Gynecol."},{"key":"10.1016\/j.bbih.2023.100635_bib11","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1038\/s41598-018-25095-3","article-title":"Salivary levels of total huntingtin are elevated in Huntington's disease patients","volume":"8","author":"Corey-Bloom","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbih.2023.100635_bib12","doi-asserted-by":"crossref","first-page":"6363","DOI":"10.3390\/ijms21176363","article-title":"Levels of interleukin-6 in saliva, but not plasma, correlate with clinical metrics in Huntington's disease patients and healthy control subjects","volume":"21","author":"Corey-Bloom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbih.2023.100635_bib13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nn.3668","article-title":"Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors","volume":"17","author":"Crotti","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbih.2023.100635_bib14","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1021\/pr0700753","article-title":"Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates","volume":"6","author":"Dalrymple","year":"2007","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.bbih.2023.100635_bib15","doi-asserted-by":"crossref","first-page":"a020412","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood\u2013brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.bbih.2023.100635_bib16","series-title":"Statistical Algorithms in Review Manager 5, Statistical Algorithms in Review Manager 5","author":"Deeks","year":"2007"},{"key":"10.1016\/j.bbih.2023.100635_bib17","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.24406","article-title":"Cerebrovascular and blood\u2013brain barrier impairments in Huntington's disease: potential implications for its pathophysiology","volume":"78","author":"Drouin-Ouellet","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.603594","article-title":"Altered gut microbiota related to inflammatory responses in patients with Huntington's disease","volume":"11","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbih.2023.100635_bib19","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.biopsych.2006.11.034","article-title":"Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study","volume":"62","author":"Duff","year":"2007","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.bbih.2023.100635_bib20","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.4049\/jimmunol.160.4.1944","article-title":"Cytokine regulation of human microglial cell IL-8 production","volume":"160","author":"Ehrlich","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbih.2023.100635_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11010-016-2762-6","article-title":"Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model","volume":"420","author":"Elcio\u011flu","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbih.2023.100635_bib22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.biopsych.2019.12.010","article-title":"Genetic risk underlying psychiatric and cognitive symptoms in Huntington's disease","volume":"87","author":"Ellis","year":"2020","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.bbih.2023.100635_bib23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/nmt.11.45","article-title":"Depression in the early stages of Huntington disease","volume":"1","author":"Epping","year":"2011","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.bbih.2023.100635_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1176\/appi.ajp.2015.14121551","article-title":"Longitudinal psychiatric symptoms in prodromal Huntington's disease: a decade of data","volume":"173","author":"Epping","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.bbih.2023.100635_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/brainsci12020161","article-title":"Understanding the burdens associated with Huntington's disease in manifest patients and care partners\u2013comparing to Parkinson's disease and the general population","volume":"12","author":"Exuzides","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.bbih.2023.100635_bib26","first-page":"159","article-title":"Immunological status in Huntington's disease","volume":"6","author":"Fiszer","year":"1991","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2307\/2339568","article-title":"Methods of determining correlation","volume":"70","author":"Further","year":"1907","journal-title":"J. Roy. Stat. Soc."},{"key":"10.1016\/j.bbih.2023.100635_bib28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1471-4159.2008.05823.x","article-title":"Induction of chemokines, MCP-1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction","volume":"108","author":"Godavarthi","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbih.2023.100635_bib29","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.biomaterials.2013.09.068","article-title":"Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system","volume":"35","author":"Godinho","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbih.2023.100635_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JPD-191699","article-title":"Plasma IL-6 and IL-17a correlate with severity of motor and non-motor symptoms in Parkinson's disease","volume":"9","author":"Green","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bbih.2023.100635_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fnmol.2019.00335","article-title":"Evaluation of biochemical and epigenetic measures of peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in Huntington\u2019s disease patients","volume":"12","author":"Gutierrez","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bbih.2023.100635_bib32","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.bbi.2012.06.001","article-title":"A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity","volume":"26","author":"Hiles","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2023.100635_bib33","doi-asserted-by":"crossref","first-page":"756 LP","DOI":"10.1136\/jnnp.2009.190702","article-title":"The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study","volume":"81","author":"Hobbs","year":"2010","journal-title":"J. Neurol. Neurosurg. & Psychiatry"},{"key":"10.1016\/j.bbih.2023.100635_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.bbih.2023.100635_bib35","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/hmg\/ddt036","article-title":"A critical role of astrocyte-mediated nuclear factor-\u03baB-dependent inflammation in Huntington's disease","volume":"22","author":"Hsiao","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbih.2023.100635_bib36","doi-asserted-by":"crossref","first-page":"7999 LP","DOI":"10.1523\/JNEUROSCI.2675-04.2004","article-title":"Activation of the I\u03baB kinase complex and nuclear factor-\u03bab contributes to mutant huntingtin neurotoxicity","volume":"24","author":"Khoshnan","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbih.2023.100635_bib37","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1093\/hmg\/ddx315","article-title":"IKK\u03b2 and mutant huntingtin interactions regulate the expression of IL-34: implications for microglial-mediated neurodegeneration in HD","volume":"26","author":"Khoshnan","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbih.2023.100635_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.29245\/2572-9411\/2016\/2.1029","article-title":"Biomarkers for Huntington's disease: a brief overview","volume":"1","author":"Killoran","year":"2016","journal-title":"J. Rare Dis. Res. Treat."},{"key":"10.1016\/j.bbih.2023.100635_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2011.02.015","article-title":"Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons","volume":"33","author":"Kraft","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbih.2023.100635_bib40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2016.09.003","article-title":"\u03b1-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function","volume":"285","author":"Kuan","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2013.12.008","article-title":"The cytokine and endocannabinoid systems are co-regulated by NF-\u03baB p65\/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients","volume":"267","author":"Laprairie","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbih.2023.100635_bib42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/jnr.10253","article-title":"Cytokines, chemokines, and cytokine receptors in human microglia","volume":"69","author":"Lee","year":"2002","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbih.2023.100635_bib43","first-page":"2327","article-title":"Activation of interleukin-6 gene expression through the NF-kappa B transcription factor","volume":"10","author":"Libermann","year":"1990","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbih.2023.100635_bib44","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.3389\/fimmu.2019.02405","article-title":"Expression of human mutant huntingtin protein in Drosophila hemocytes impairs immune responses","volume":"10","author":"Lin","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbih.2023.100635_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.brainres.2018.06.009","article-title":"Intravenous immunoglobulin ameliorates motor and cognitive deficits and neuropathology in R6\/2 mouse model of Huntington's disease by decreasing mutant huntingtin protein level and normalizing NF-\u03baB signaling pathway","volume":"1697","author":"Liu","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.bbih.2023.100635_bib46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/hmg\/9.3.387","article-title":"Huntingtin is required for normal hematopoiesis","volume":"9","author":"Metzler","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbih.2023.100635_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141793","article-title":"Mutant huntingtin does not affect the intrinsic phenotype of human Huntington's disease T lymphocytes","volume":"10","author":"Miller","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbih.2023.100635_bib48","first-page":"2893","article-title":"RNA-Seq of Huntington's disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation","volume":"25","author":"Miller","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbih.2023.100635_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/srep46740","article-title":"Allele-selective suppression of mutant huntingtin in primary human blood cells","volume":"7","author":"Miller","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbih.2023.100635_bib50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.biopsych.2018.09.030","article-title":"Interleukin-6 induced by social stress promotes a unique transcriptional signature in the monocytes that facilitate anxiety","volume":"85","author":"Niraula","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.bbih.2023.100635_bib51","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000107423","article-title":"Impact of gender and menstrual cycle phase on plasma cytokine concentrations","volume":"14","author":"O'Brien","year":"2007","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.bbih.2023.100635_bib52","article-title":"Wild-type huntingtin regulates human macrophage function","volume":"10","author":"O'Regan","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbih.2023.100635_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1037\/0021-9010.90.1.175","article-title":"On the use of beta coefficients in meta-analysis","volume":"90","author":"Peterson","year":"2005","journal-title":"J. Appl. Psychol."},{"key":"10.1016\/j.bbih.2023.100635_bib54","article-title":"Behavioral- and blood-based biomarkers for Huntington's disease: studies on the R6\/1 mouse model with prospects for early diagnosis and monitoring of the disease","volume":"23","author":"Podlacha","year":"2022","journal-title":"Brain, Behav. Immun. - Heal."},{"key":"10.1016\/j.bbih.2023.100635_bib55","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hbm.21008","article-title":"Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study","volume":"32","author":"Politis","year":"2011","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.bbih.2023.100635_bib56","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","article-title":"Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers","volume":"83","author":"Politis","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbih.2023.100635_bib57","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/mds.25075","article-title":"The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis","volume":"27","author":"Pringsheim","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbih.2023.100635_bib58","doi-asserted-by":"crossref","first-page":"E4676","DOI":"10.1073\/pnas.1614943114","article-title":"KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients","volume":"114","author":"Quinti","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbih.2023.100635_bib59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbi.2016.07.004","article-title":"Increased irritability, anxiety, and immune reactivity in transgenic Huntington's disease monkeys","volume":"58","author":"Raper","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbih.2023.100635_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163479","article-title":"Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington's disease","volume":"11","author":"Rodrigues","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbih.2023.100635_bib61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington's disease: a clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.bbih.2023.100635_bib62","first-page":"16","article-title":"Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbih.2023.100635_bib63","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib64","article-title":"Cochrane consumers and communication review group reviews: mata-analysis","volume":"1\u20136","author":"Ryan","year":"2016","journal-title":"Cochrane Consum. Commun. Rev. Gr."},{"key":"10.1016\/j.bbih.2023.100635_bib65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1179\/1743132812Y.0000000073","article-title":"Oxidative stress and inflammation biomarkers in the blood of patients with Huntington's disease","volume":"34","author":"S\u00e1nchez-L\u00f3pez","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.bbih.2023.100635_bib66","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/mds.870130609","article-title":"Unified Huntington's disease rating scale: a follow up","volume":"13","author":"Siesling","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbih.2023.100635_bib67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JHD-170273","article-title":"A critical evaluation of wet biomarkers for Huntington's disease: current status and ways forward","volume":"7","author":"Silajd\u017ei\u0107","year":"2018","journal-title":"J. Huntingtons. Dis."},{"key":"10.1016\/j.bbih.2023.100635_bib68","doi-asserted-by":"crossref","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington's disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbih.2023.100635_bib69","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/hmg\/ddy202","article-title":"TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31","volume":"27","author":"Simmons","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbih.2023.100635_bib70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/fcp.12596","article-title":"Impact of interleukin-6 on drug transporters and permeability in the hCMEC\/D3 blood\u2013brain barrier model","volume":"35","author":"Simon","year":"2021","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.bbih.2023.100635_bib71","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood\u2013brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib72","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.3390\/molecules23123167","article-title":"Characterization of endocannabinoid-metabolizing enzymes in human peripheral blood mononuclear cells under inflammatory conditions","volume":"23","author":"Szafran","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bbih.2023.100635_bib73","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib74","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib75","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-2094-7-16","article-title":"Mechanisms of tumor necrosis factor-\u03b1-induced interleukin-6 synthesis in glioma cells","volume":"7","author":"Tanabe","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bbih.2023.100635_bib76","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/brain\/awt355","article-title":"HTT-lowering reverses Huntington's disease immune dysfunction caused by NF\u03baB pathway dysregulation","volume":"137","author":"Tr\u00e4ger","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.bbih.2023.100635_bib77","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1177\/1352458516672015","article-title":"Increased cerebrospinal fluid metalloproteinase-2 and interleukin-6 are associated with albumin quotient in neuromyelitis optica: their possible role on blood_brain barrier disruption","volume":"23","author":"Uchida","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.bbih.2023.100635_bib78","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: Reliability and consistency","volume":"11","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbih.2023.100635_bib79","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ana.25647","article-title":"Early intrathecal T helper 17.1 cell activity in Huntington disease","volume":"87","author":"von Essen","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbih.2023.100635_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-020-00379-3","article-title":"Interleukin-6 deficiency exacerbates Huntington's disease model phenotypes","volume":"15","author":"Wertz","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbih.2023.100635_bib81","series-title":"Degradation of Tryptophan in Neurodegenerative Disorders BT - Tryptophan, Serotonin, and Melatonin: Basic Aspects and Applications","first-page":"133","author":"Widner","year":"1999"},{"key":"10.1016\/j.bbih.2023.100635_bib82","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1586\/14737175.8.12.1779","article-title":"Immune markers for Huntington's disease?","volume":"8","author":"Wild","year":"2008","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.bbih.2023.100635_bib83","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/21678421.2020.1813310","article-title":"Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients","volume":"22","author":"Wosiski-Kuhn","year":"2021","journal-title":"Amyotroph. Lateral Scler. Front. Degener."},{"key":"10.1016\/j.bbih.2023.100635_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155556","article-title":"Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment","volume":"144","author":"Yap","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.bbih.2023.100635_bib85","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/mds.25654","article-title":"Unified Huntington's disease rating scale for advanced patients: validation and follow-up study","volume":"28","author":"Youssov","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbih.2023.100635_bib86","doi-asserted-by":"crossref","first-page":"43910","DOI":"10.1074\/jbc.M403884200","article-title":"The fanconi anemia proteins functionally interact with the protein kinase regulated by RNA (PKR)","volume":"279","author":"Zhang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbih.2023.100635_bib87","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cell.2015.10.067","article-title":"Establishment and dysfunction of the blood-brain barrier","volume":"163","author":"Zhao","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbih.2023.100635_bib88","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.parkreldis.2012.09.012","article-title":"The influence of gender on phenotype and disease progression in patients with Huntington's disease","volume":"19","author":"Zielonka","year":"2013","journal-title":"Parkinsonism Relat. Disorders"}],"container-title":["Brain, Behavior, &amp; Immunity - Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354623000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666354623000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:33:07Z","timestamp":1762986787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666354623000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":88,"alternative-id":["S2666354623000492"],"URL":"https:\/\/doi.org\/10.1016\/j.bbih.2023.100635","relation":{},"ISSN":["2666-3546"],"issn-type":[{"value":"2666-3546","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-6 as a marker of Huntington's disease progression: Systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, & Immunity - Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbih.2023.100635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100635"}}